These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26096558)

  • 1. About the gut microbiome as a pharmacological target in atherosclerosis.
    Witjes JJ; van Raalte DH; Nieuwdorp M
    Eur J Pharmacol; 2015 Sep; 763(Pt A):75-8. PubMed ID: 26096558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut Microbiota and Energy Expenditure in Health and Obesity.
    Bakker GJ; Zhao J; Herrema H; Nieuwdorp M
    J Clin Gastroenterol; 2015; 49 Suppl 1():S13-9. PubMed ID: 26447957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Intestinal Microbiome in Lipid and Glucose Metabolism in Diabetes Mellitus.
    van Olden C; Groen AK; Nieuwdorp M
    Clin Ther; 2015 Jun; 37(6):1172-7. PubMed ID: 25922340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low-grade inflammation and the development of obesity and diabetes.
    Bleau C; Karelis AD; St-Pierre DH; Lamontagne L
    Diabetes Metab Res Rev; 2015 Sep; 31(6):545-61. PubMed ID: 25352002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.
    Cammarota G; Ianiro G; Cianci R; Bibbò S; Gasbarrini A; Currò D
    Pharmacol Ther; 2015 May; 149():191-212. PubMed ID: 25561343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting gut microbiota as a possible therapy for diabetes.
    He C; Shan Y; Song W
    Nutr Res; 2015 May; 35(5):361-7. PubMed ID: 25818484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases.
    Konturek PC; Haziri D; Brzozowski T; Hess T; Heyman S; Kwiecien S; Konturek SJ; Koziel J
    J Physiol Pharmacol; 2015 Aug; 66(4):483-91. PubMed ID: 26348073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal Immunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic Cardiovascular Diseases.
    Yamashita T; Kasahara K; Emoto T; Matsumoto T; Mizoguchi T; Kitano N; Sasaki N; Hirata K
    Circ J; 2015; 79(9):1882-90. PubMed ID: 26212124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut Microbiota and Atherosclerosis.
    Li DY; Tang WHW
    Curr Atheroscler Rep; 2017 Aug; 19(10):39. PubMed ID: 28842845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies.
    van den Munckhof ICL; Kurilshikov A; Ter Horst R; Riksen NP; Joosten LAB; Zhernakova A; Fu J; Keating ST; Netea MG; de Graaf J; Rutten JHW
    Obes Rev; 2018 Dec; 19(12):1719-1734. PubMed ID: 30144260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal microbiota transplantation does not alter bacterial translocation and visceral adipose tissue inflammation in individuals with obesity.
    Bakker GJ; Meijnikman AS; Scheithauer TP; Davids M; Aydin Ö; Boerlage TCC; de Brauw LM; van de Laar AW; Gerdes VE; Groen AK; van Raalte DH; Herrema H; Nieuwdorp M
    Obes Sci Pract; 2022 Feb; 8(1):56-65. PubMed ID: 35127122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gut microbiome in atherosclerotic cardiovascular disease.
    Jie Z; Xia H; Zhong SL; Feng Q; Li S; Liang S; Zhong H; Liu Z; Gao Y; Zhao H; Zhang D; Su Z; Fang Z; Lan Z; Li J; Xiao L; Li J; Li R; Li X; Li F; Ren H; Huang Y; Peng Y; Li G; Wen B; Dong B; Chen JY; Geng QS; Zhang ZW; Yang H; Wang J; Wang J; Zhang X; Madsen L; Brix S; Ning G; Xu X; Liu X; Hou Y; Jia H; He K; Kristiansen K
    Nat Commun; 2017 Oct; 8(1):845. PubMed ID: 29018189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Microbiota and Its Metabolites in Atherosclerosis Development.
    Pieczynska MD; Yang Y; Petrykowski S; Horbanczuk OK; Atanasov AG; Horbanczuk JO
    Molecules; 2020 Jan; 25(3):. PubMed ID: 32013236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Sleep Disruption Alters Gut Microbiota, Induces Systemic and Adipose Tissue Inflammation and Insulin Resistance in Mice.
    Poroyko VA; Carreras A; Khalyfa A; Khalyfa AA; Leone V; Peris E; Almendros I; Gileles-Hillel A; Qiao Z; Hubert N; Farré R; Chang EB; Gozal D
    Sci Rep; 2016 Oct; 6():35405. PubMed ID: 27739530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal Immunity and Gut Microbiota in Atherogenesis.
    Yamashita T
    J Atheroscler Thromb; 2017 Feb; 24(2):110-119. PubMed ID: 27928097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Gut Microbiota-Brain Axis by Probiotics, Prebiotics, and Diet.
    Liu X; Cao S; Zhang X
    J Agric Food Chem; 2015 Sep; 63(36):7885-95. PubMed ID: 26306709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal Microbiota Metabolism and Atherosclerosis.
    Liu TX; Niu HT; Zhang SY
    Chin Med J (Engl); 2015 Oct; 128(20):2805-11. PubMed ID: 26481750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The relationship between gut microbiota and cardiovascular diseases].
    Gerardi V; Del Zompo F; D'Aversa F; Gasbarrini A
    G Ital Cardiol (Rome); 2016 Jan; 17(1):11-4. PubMed ID: 26901254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of natural products against atherosclerosis: Targeting on gut microbiota.
    Zhao X; Oduro PK; Tong W; Wang Y; Gao X; Wang Q
    Pharmacol Res; 2021 Jan; 163():105362. PubMed ID: 33285231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota in obesity and metabolic disorders.
    Sanz Y; Santacruz A; Gauffin P
    Proc Nutr Soc; 2010 Aug; 69(3):434-41. PubMed ID: 20540826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.